CJRB-101

CJRB-101 is a live, novel therapeutic bacterial strain developed for its immunostimulating and antineoplastic (anti-cancer) activities. Upon administration, CJRB-101 activates M1 macrophages and induces the repolarization of tumor-promoting M2 macrophages into anti-tumor M1 macrophages, thereby enhancing immune-mediated tumor suppression. This mechanism increases cytotoxic T lymphocyte (CD8+ T cell) activity within the tumor microenvironment. The drug’s anti-cancer effects are mediated through Toll-like receptor 4 (TLR4)-dependent stimulation of key immune cell populations, including macrophages and CD8+ T cells. Preclinical studies have demonstrated efficacy in humanized mouse models of non-small cell lung cancer and other solid tumors. Clinical development is ongoing for advanced cancers such as non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and small cell lung cancer—primarily in combination with pembrolizumab to address resistance to immune checkpoint inhibitors.

Other names

therapeutic bacterial strain CJRB-101